1921
Volume 89, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Successful and sustained efforts have been made to curtail the major cholera epidemic that occurred in Haiti in 2010 with the promotion of hygiene and sanitation measures, training of health personnel and establishment of treatment centers nationwide. Oral cholera vaccine (OCV) was introduced by the Haitian Ministry of Health as a pilot project in urban and rural areas. This paper reports the successful OCV pilot project led by GHESKIO Centers in the urban slums of Port-au-Prince where 52,357 persons received dose 1 and 90.8% received dose 2; estimated coverage of the at-risk community was 75%. This pilot study demonstrated the effort, community mobilization, and organizational capacity necessary to achieve these results in a challenging setting. The OCV intervention paved the way for the recent launching of a national cholera vaccination program integrated in a long-term ambitious and comprehensive plan to address Haiti's critical need in water security and sanitation.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.13-0171
2013-10-09
2018-12-13
Loading full text...

Full text loading...

/deliver/fulltext/14761645/89/4/671.html?itemId=/content/journals/10.4269/ajtmh.13-0171&mimeType=html&fmt=ahah

References

  1. Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery B, Clemens J, , 2012. The global burden of cholera. Bull World Health Organ 90: 209218.[Crossref] [Google Scholar]
  2. Son MS, Megli CJ, Kovacikova G, Qadri F, Taylor RK, , 2011. Characterization of Vibrio cholerae O1 El Tor biotype variant clinical isolates from Bangladesh and Haiti, including a molecular genetic analysis of virulence genes. J Clin Microbiol 49: 37393749.[Crossref] [Google Scholar]
  3. Goodgame RW, Greenough WB, , 1975. III Cholera in Africa: a message for the West. Ann Intern Med 82: 101106.[Crossref] [Google Scholar]
  4. Seas C, Miranda J, Gil AI, Leon-Barua R, Patz J, Huq A, Colwell RR, Sack RB, , 2000. New insights on the emergence of cholera in Latin America during 1991: the Peruvian experience. Am J Trop Med Hyg 62: 513517. [Google Scholar]
  5. Centers for Disease Control and Prevention (CDC), 2010. Cholera outbreak—Haiti, October 2010. MMWR Morb Mortal Wkly Rep 59: 1411. [Google Scholar]
  6. Chin CS, Sorenson J, Harris JB, Robins WP, Charles RC, Jean-Charles RR, Bullard J, Webster DR, Kasarskis A, Peluso P, Paxinos EE, Yamaichi Y, Calderwood SB, Mekalanos JJ, Schadt EE, Waldor MK, , 2011. The origin of the Haitian cholera outbreak strain. N Engl J Med 364: 3342.[Crossref] [Google Scholar]
  7. Haiti Ministry of Public Health and Population. Available at: http://www.mspp.gouv.ht/site/index.php?option=com_content&view=article&id=120&Itemid=1. Accessed November 7, 2012. [Google Scholar]
  8. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou GA, Mintz ED, Steenland MW, Vertefeuille JF, Tappero JW, , 2013. Cholera surveillance during the Haiti epidemic: the first 2 years. N Engl J Med 368: 599609.[Crossref] [Google Scholar]
  9. Sullivan CA, Meigh JR, Giacomello AM, , 2003. The Water Poverty Index: development and application at the community scale. Nat Resour Forum 27: 189199.[Crossref] [Google Scholar]
  10. Waldman RJ, Mintz ED, Papowitz HE, , 2013. The cure for cholera: improving access to safe water and sanitation. N Engl J Med 368: 592594.[Crossref] [Google Scholar]
  11. Periago MR, Frieden TR, Tappero JW, De Cock KM, Aasen B, Andrus JK, , 2012. Elimination of cholera transmission in Haiti and the Dominican Republic. Lancet 379: e12e13.[Crossref] [Google Scholar]
  12. Nelson EJ, Nelson DS, Salam MA, Sack DA, , 2011. Antibiotics for both moderate and severe cholera. N Engl J Med 364: 57.[Crossref] [Google Scholar]
  13. Ivers LC, Farmer PE, Pape WJ, , 2012. Oral cholera vaccine and integrated cholera control in Haiti. Lancet 379: 20262028.[Crossref] [Google Scholar]
  14. Ivers LC, Farmer P, Almazor CP, Leandre F, , 2010. Five complimentary interventions to slow cholera. Haiti Lancet 376: 20482051.[Crossref] [Google Scholar]
  15. Farmer P, Almazor CP, Bahnsen ET, Barry D, Bazile J, Bloom BR, Bose N, Brewer T, Calderwood SB, Clemens JD, Cravioto A, Eustache E, Jérôme G, Gupta N, Harris JB, Hiatt HH, Holstein C, Hotez PJ, Ivers LC, Kerry VB, Koenig SP, Larocque RC, Léandre F, Lambert W, Lyon E, Mekalanos JJ, Mukherjee JS, Oswald C, Pape JW, Gretchko Prosper A, Rabinovich R, Raymonville M, Réjouit JR, Ronan LJ, Rosenberg ML, Ryan ET, Sachs JD, Sack DA, Surena C, Suri AA, Ternier R, Waldor MK, Walton D, Weigel JL, , 2011. Meeting cholera's challenge to Haiti and the world: a joint statement on cholera prevention and care. PLoS Negl Trop Dis 5: e1145.[Crossref] [Google Scholar]
  16. Newton AE, Heiman KE, Schmitz A, Török T, Apostolou A, Hanson H, Gounder P, Bohm S, Kurkjian K, Parsons M, Talkington D, Stroika S, Madoff LC, Elson F, Sweat D, Cantu V, Akwari O, Mahon BE, Mintz ED, , 2011. Cholera in United States associated with epidemic in Hispaniola. Emerg Infect Dis 17: 21662168.[Crossref] [Google Scholar]
  17. Ryan ET, Madoff LC, Ferraro MJ, , 2011. Case records of the Massachusetts General Hospital. Case 20-2011. A 30-year-old man with diarrhea after a trip to the Dominican Republic. N Engl J Med 364: 25362541.[Crossref] [Google Scholar]
  18. Shin S, Desai SN, Sah BK, Clemens JD, , 2011. Oral vaccines against cholera. Clin Infect Dis 52: 13431349.[Crossref] [Google Scholar]
  19. Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Han SH, Attridge S, Donner A, Ganguly NK, Bhattacharya SK, Nair GB, Clemens JD, Lopez AL, , 2011. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis 5: e1289.[Crossref] [Google Scholar]
  20. Sinclair D, Abba K, Zaman K, Qadri F, Graves PM, , 2011. Oral vaccines for preventing cholera. Cochrane Database Syst Rev Mar 16 (3): CD008603. [Google Scholar]
  21. Lucas ME, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, Ali M, Ansaruzzaman M, Amos J, Macuamule A, Cavailler P, Guerin PJ, Mahoudeau C, Kahozi-Sangwa P, Chaignat CL, Barreto A, Songane FF, Clemens JD, , 2005. Effectiveness of a mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 352: 757767.[Crossref] [Google Scholar]
  22. Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, Hang PV, Rao MR, Trach DD, , 1997. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349: 231235.[Crossref] [Google Scholar]
  23. Pape JW, Johnson WD, Jr Fitzgerald DW, , 2010. The earthquake in Haiti: dispatch from Port-au-Prince. N Engl J Med 362: 575577.[Crossref] [Google Scholar]
  24. Pape JW, Deschamps MM, Ford H, Joseph P, Johnson WD, Jr Fitzgerald DW, , 2010. The GHESKIO refugee camp after the earthquake in Haiti–dispatch 2 from Port-au-Prince. N Engl J Med 362: e27.[Crossref] [Google Scholar]
  25. Pape JW, Rouzier V, Ford H, Joseph P, Johnson WD, Jr Fitzgerald DW, , 2010. The GHESKIO field hospital and clinics after the earthquake in Haiti: dispatch 3 from Port-au-Prince. N Engl J Med 362: e34.[Crossref] [Google Scholar]
  26. Ali M, Sur D, You YA, Kanungo S, Sah B, Manna B, Puri M, Wierzba TF, Donner A, Nair GB, Bhattacharya SK, Dhingra MS, Deen JL, Lopez AL, Clemens J, , 2013. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India. Clin Infect Dis 56: 11231131.[Crossref] [Google Scholar]
  27. PAHO Position on Cholera Vaccination in Haiti, 2010. Version October 27, 2010. Washington, DC: Pan American Health Organization.
  28. World Health Organization, 2010. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 85: 117128. [Google Scholar]
  29. Date KA, Vicari A, Hyde TB, Mintz E, Danovaro-Holliday MC, Henry A, Tappero JW, Roels TH, Abrams J, Burkholder BT, Ruiz-Matus C, Andrus J, Dietz V, , 2011. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010–2011. Emerg Infect Dis 17: 21052112.[Crossref] [Google Scholar]
  30. The Task Force for Global Health/Partners in Health, 2012. Stop Cholera: Coalition for Cholera Prevention and Control. Summary conference proceedings, unpublished conference paper, March 15–16, 2012, Atlanta, GA. [Google Scholar]
  31. Waldor MK, Hotez PJ, Clemens JD, , 2010. A national cholera vaccine stockpile: a new humanitarian and diplomatic resource. N Engl J Med 363: 22792282.[Crossref] [Google Scholar]
  32. Khatib AM, Ali M, von Seidlein L, Kim DR, Hashim R, Reyburn R, Ley B, Thriemer K, Enwere G, Hutubessy R, Aguado MT, Kieny MP, Lopez AL, Wierzba TF, Ali SM, Saleh AA, Mukhopadhyay AK, Clemens J, Jiddawi MS, Deen J, , 2012. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis 12: 837844.[Crossref] [Google Scholar]
  33. Longini IM, Jr Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD, , 2007. Controlling endemic cholera with oral vaccines. PLoS Med 4: e336.[Crossref] [Google Scholar]
  34. Technical Advisory Group on Vaccine-Preventable Diseases, 2011. Final Report from the XIX TAG Meeting, July 6–8, 2011, Buenos Aires, Argentina. [Google Scholar]
  35. Bulletin MSPP Janvier–Mars, 2013. Available at: http://issuu.com/jean-juniorjoseph/docs/bulletin_mspp_janvier-mars_2013_-_140513. Accessed August 4, 2013.
  36. Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Preziosi MP, Zuber PL, Perea W, Hugonnet S, Dellepiane de Rey Tolve N, Tevi-Benissan C, Clark TA, Mayer LW, Novak R, Messonier NE, Berlier M, Toboe D, Nshimirimana D, Mihigo R, Aguado T, Diomandé F, Kristiansen PA, Caugant DA, Laforce FM, , 2012. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 30 (Suppl 2): B40B45.[Crossref] [Google Scholar]
  37. Ouandaogo CR, Yaméogo TM, Diomandé FV, Sawadogo C, Ouédraogo B, Ouédraogo-Traoré R, Pezzoli L, Djingarey MH, Mbakuliyemo N, Zuber PL, , 2012. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine 30 (Suppl 2): B46B51.[Crossref] [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.13-0171
Loading
/content/journals/10.4269/ajtmh.13-0171
Loading

Data & Media loading...

  • Received : 29 Mar 2013
  • Accepted : 14 Jun 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error